

 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 980034.417C5	APPLICATION NO. 10/762,210
	APPLICANTS Ronald J. Berenson et al.	
	FILING DATE January 20, 2004	GROUP ART UNIT 1651

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,464,456	08/07/84	Fujikawa et al.	430	281	
	AB	4,654,210	03/31/87	Kung et al.	424	85	
	AC	4,844,893	07/04/89	Honsik et al.	424	85.8	
	AD	5,057,423	10/15/91	Hiserodt et al.	435	240.23	
	AE	5,106,746	04/21/92	Ho	435	240.25	
	AF	5,116,964	05/26/92	Capon et al.	536	27	
	AG	5,166,320	11/24/92	Wu et al.	530	395	
	AH	5,223,426	06/29/93	Skibbens et al.	435	240.27	
	AI	5,260,422	11/09/93	Clark et al.	530	403	
	AJ	5,336,603	08/09/94	Capon et al.	435	69.7	
	AK	5,434,131	07/18/95	Linsley et al.	514	2	
	AL	5,468,635	11/21/95	Komiya et al.	435	240.21	
	AM	5,521,288	05/28/96	Linsley et al.	530	387.3	
	AN	5,529,921	06/25/96	Peterson et al.	435	240.2	
	AO	5,547,963	08/20/96	Poindron et al.	514	317	
	AP	5,554,512	09/10/96	Lyman et al.	435	69.5	
	AQ	5,595,881	01/21/97	Kendrick et al.	435	7.21	
	AR	5,635,354	06/03/97	Kourilsky et al.	435	6	
	AS	5,648,219	07/15/97	MacKay et al.	435	6	
	AT	5,677,139	10/14/97	Johnson et al.	435	29	
	AU	5,688,915	11/18/97	Ron et al.	530	380	
	AV	5,728,388	03/17/98	Terman	424	237.1	
	AW	5,738,852	04/14/98	Robinson et al.	424	199.1	
	AX	5,759,546	06/02/98	Weinberg et al.	424	179.1	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 980034.417C5	APPLICATION NO. 10/762,210
	APPLICANTS Ronald J. Berenson et al.	
	FILING DATE January 20, 2004	GROUP ART UNIT 1651

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,766,947	06/16/98	Ritterhause et al.	435	334	
	AB	5,773,573	06/30/98	Holms	530	327	
	AC	5,776,966	07/07/98	North	514	410	
	AD	5,788,963	08/04/98	Murphy et al.	424	93.21	
	AE	5,824,551	10/20/98	Damme et al.	435	375	
	AF	5,827,642	10/27/98	Riddell et al.	435	2	
	AG	5,830,462	11/03/98	Crabtree et al.	424	93.21	
	AH	5,830,473	11/03/98	Thierfelder	424	172.1	
	AI	5,837,447	11/17/98	Gorski	435	6	
	AJ	5,843,435	12/01/98	Slavin	424	93.71	
	AK	5,843,635	12/01/98	Schlossman et al.	435	5	
	AL	5,849,589	12/15/98	Tedder et al.	435	377	
	AM	5,851,756	12/22/98	Steinman et al.	435	2	
	AN	5,853,719	12/29/98	Nair et al.	424	93.21	
	AO	5,861,486	01/19/99	Devore et al.	530	356	
	AP	5,869,270	02/09/99	Rhode et al.	435	7.24	
	AQ	5,869,337	02/09/99	Crabtree et al.	435	372.3	
	AR	5,871,728	02/16/99	Thomson et al.	424	93.7	
	AS	5,871,753	02/16/99	Crabtree et al.	424	280.1	
	AT	5,872,222	02/16/99	Chang	530	391.1	
	AU	5,874,307	02/23/99	Ohno et al.	435	372.3	
	AV	5,877,397	03/02/99	Lonberg et al.	800	2	
	AW	5,883,223	03/16/99	Gray	530	328	
	AX	5,888,511	03/30/99	Skurkovich et al.	424	145.1	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 980034.417C5	APPLICATION NO. 10/762,210
	APPLICANTS Ronald J. Berenson et al.	
	FILING DATE January 20, 2004	GROUP ART UNIT 1651

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,910,403	06/08/99	Hellerstein	435	4	
	AB	5,928,639	06/27/99	Slavin	424	93.71	
	AC	5,935,575	08/10/99	Lenardo et al.	424	184.1	
	AD	5,962,318	10/05/99	Rooney et al.	435	325	
	AE	5,962, 320	10/05/99	Robinson	435	366	
	AF	5,962,406	10/05/99	Armitage et al.	514	8	
	AG	5,976,533	11/02/99	Skibbens et al.	424	144.1	
	AH	5,980,892	11/09/99	Skibbens et al.	424	144.1	
	AI	5,981,724	11/09/99	Armitage et al.	536	23.5	
	AJ	5,985,552	11/16/99	Howell et al.	435	6	
	AK	5,989,546	11/23/99	Lenardo	424	184.1	
	AL	5,994,126	11/30/99	Steinman et al.	435	325	
	AM	6,001,365	12/14/99	Peterson et al.	424	193.1	
	AN	6,004,807	12/21/99	Banchereau et al.	435	325	
	AO	6,004,942	12/21/99	Firestein et al.	514	44	
	AP	6,008,188	12/28/99	Oishi et al.	514	2	
	AQ	6,011,018	01/04/00	Crabtree et al.	514	31	
	AR	6,017,527	01/25/00	Maraskovsky et al.	424	93.71	
	AS	6,040,177	03/21/00	Riddell et al.	435	372.3	
	AT	6,043,082	03/28/00	Crabtree et al.	435	320.1	
	AU	6,046,047	04/04/00	Crabtree et al.	435	320.1	
	AV	6,048,526	04/11/00	Skibbens et al.	424	144.1	
	AW	6,063,625	05/16/00	Crabtree et al.	435	375	
	AX	6,074,635	06/13/00	Abrignani	424	85.1	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 980034.417C5	APPLICATION NO. 10/762,210
	APPLICANTS Ronald J. Berenson et al.	
	FILING DATE January 20, 2004	GROUP ART UNIT 1651

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,080,409	06/27/00	Laus et al.	424	192.1	
	AB	6,083,503	07/04/00	Lenardo	424	184.1	
	AC	6,090,387	07/18/00	Howell et al.	424	185.1	
	AD	6,117,982	09/12/00	Chang	530	391.1	
	AE	6,120,766	09/19/00	Hale et al.	424	130.1	
	AF	6,121,044	09/19/00	Peshwa et al.	435	325	
	AG	6,126,945	10/03/00	Terman et al.	424	237.1	
	AH	6,140,120	10/31/00	Crabtree et al.	435	372.3	
	AI	6,143,291	11/07/00	June et al.	424	93.21	
	AJ	6,143,292	11/07/00	Slavin	424	93.7	
	AK	6,159,461	12/12/00	Besmer et al.	424	85.1	
	AL	6,165,785	12/26/00	Ogle et al.	435	347	
	AM	6,165,787	12/26/00	Crabtree et al.	435	372.3	
	AN	6,171,799	01/09/01	Skibbens et al.	435	7.1	
	AO	6,180,097	01/30/01	Terman	424	93.1	
	AP	6,190,655	02/20/01	Lyman et al.	424	85.1	
	AQ	6,200,806	03/13/01	Thomson	435	366	
	AR	6,203,487	03/20/01	Consigny	600	12	
	AS	6,210,669	04/03/01	Aruffo et al.	424	144.1	
	AT	6,221,351	04/24/01	Terman	424	93.71	
	AU	6,221,352	04/24/01	Howell et al.	424	139.1	
	AV	6,225,118	05/01/01	Grant et al.	435	347	
	AW	6,232,445	05/15/01	Rhode et al.	530	387.3	
	AX	6,251,385	06/26/01	Terman	424	93.7	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 980034.417C5	APPLICATION NO. 10/762,210
	APPLICANTS Ronald J. Berenson et al.	
	FILING DATE January 20, 2004	GROUP ART UNIT 1651

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,258,357	07/10/01	Spaner	424	93.71	
	AB	6,284,879	09/04/01	Faustman	536	23.1	
	AC	6,290,955	09/18/01	Thierfelder	424	130.1	
	AD	6,309,645	10/30/01	Rhode et al.	424	192.1	
	AE	6,333,032	12/25/01	Skurkovich et al.	424	130.1	
	AF	6,338,845	01/15/02	Terman	424	93.1	
	AG	6,340,461	01/22/02	Terman	424	193.1	
	AH	6,355,479	03/12/02	Webb et al.	435	325	
	AI	6,362,694	03/26/02	Doberenz	331	57	
	AJ	6,399,054	06/04/02	Casorati et al.	424	93.21	
	AK	6,406,699	06/18/02	Wood	424	184.1	
	AL	6,447,765	09/10/02	Horwitz	424	85.1	
	AM	6,455,299	09/24/02	Steinman et al.	435	235.1	
	AN	6,461,806	10/08/02	Hellerstein	435	4	
	AO	6,464,973	10/15/02	Levitsky et al.	424	93.21	
	AP	6,465,251	10/15/02	Schultze et al.	435	377	
	AQ	6,488,933	12/03/02	Cohen et al.	424	185.1	
	AR	6,534,055	03/18/03	June et al.	424	93.71	
	AS	6,544,787	04/08/03	Slavin	435	372	
	AT	6,566,082	05/20/03	Weinberg et al.	435	7.24	
	AU	6,576,428	06/10/03	Assenmacher et al.	435	7.1	
	AV	6,576,466	06/10/03	Jungfer et al.	435	372.3	
	AW	6,602,709	08/05/03	Albert et al.	435	372	
	AX	6,610,542	08/26/03	Bell et al.	435	377	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 980034.417C5	APPLICATION NO. 10/762,210
	APPLICANTS Ronald J. Berenson et al.	
	FILING DATE January 20, 2004	GROUP ART UNIT 1651

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,656,471	12/02/03	Sastry et al.	424	188.1	
	AB	6,689,605	02/10/04	Mountz et al.	435	320.1	
	AC	6,692,746	02/17/04	Terman et al.	424	184.1	
	AD	6,719,972	04/13/04	Gribben et al.	424	154.1	
	AE	6,867,041	03/15/05	Berenson et al.	435	377	
	AF	6,887,466	05/03/05	June et al.	424	93.71	
	AG	6,905,680	06/14/05	June et al.	424	93.71	
	AH	6,905,874	06/14/05	Berenson et al.	435	375	
	AI	7,232,566	06/19/07	June et al.	424	93.71	
	AJ	2001/0012514	08/09/01	Skurkovich et al.	424	143.1	
	AK	2001/0028879	10/11/01	Spaner	424	93.7	
	AL	2001/0051151	12/13/01	Lamb, Jr.	424	93.7	
	AM	2002/0004041	01/10/02	Albert et al.	424	93.21	
	AN	2002/0006409	01/17/02	Wood	424	184.1	
	AO	2002/0009448	01/24/02	Weiner et al.	424	154.1	
	AP	2002/0031496	03/14/02	Firestein et al.	424	93.6	
	AQ	2002/0034513	03/21/02	Rhode et al.	424	184.1	
	AR	2002/0034517	03/21/02	Brasel et al.	424	192.1	
	AS	2002/0037860	03/28/02	D'Andrea et al.	514	19	
	AT	2002/0039569	04/04/02	Jungfer et al.	424	85.2	
	AU	2002/0058019	05/16/02	Berenson et al.	424	93.7	
	AV	2002/0076407	06/20/02	June et al.	424	143.1	
	AW	2002/0091079	07/11/02	Rhode et al.	514	12	
	AX	2002/0115214	08/22/02	June et al.	435	372.3	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 980034.417C5	APPLICATION NO. 10/762,210
	APPLICANTS Ronald J. Berenson et al.	
	FILING DATE January 20, 2004	GROUP ART UNIT 1651

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	2002/0119568	08/29/02	Berenson et al.	435	446	
	AB	2002/0119571	08/29/02	Ritter et al.	435	456	
	AC	2002/0123472	09/05/02	Faustman	514	44	
	AD	2002/0146396	10/10/02	Albert et al.	424	93.21	
	AE	2002/0155604	10/24/02	Ledbetter et al.	435	372.3	
	AF	2002/0164331	11/07/02	Exley et al.	424	144.1	
	AG	2002/0176850	11/28/02	Slavin	424	93.21	
	AH	2002/0177554	11/28/02	Verheijden et al.	514	12	
	AI	2002/0197716	12/26/02	Flyer et al.	435	372	
	AJ	2003/0099643	05/29/03	June et al.	424	144.1	
	AK	2003/0113328	06/19/03	Roifman et al.	424	146.1	
	AL	2003/0113341	06/19/03	Lynch et al.	424	185.1	
	AM	2003/0118659	06/26/03	August et al.	424	491	
	AN	2003/0119185	06/26/03	Berenson et al.	435	372	
	AO	2003/0165531	09/04/03	Lynch et al.	424	192.1	
	AP	2003/0176378	09/18/03	Weiner et al.	514	44	
	AQ	2003/0190323	10/09/03	Cohen et al.	424	185.1	
	AR	2003/0219463	11/27/03	Falkenburg et al.	424	277.1	
	AS	2003/0235908	12/25/03	Berenson et al.	435	372	
	AT	2004/0023377	02/05/04	Assenmacher et al.	435	372	
	AU	2004/0037845	02/26/04	Brasel et al.	424	185.1	
	AV	2004/0072749	04/15/04	Zochoer et al.	514	12	
	AW	2004/0156860	08/12/04	Weiner et al.	424	185.1	
	AX	2004/0157792	08/12/04	Mountz et al.	514	44	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 980034.417C5	APPLICATION NO. 10/762,210
	APPLICANTS Ronald J. Berenson et al.	
	FILING DATE January 20, 2004	GROUP ART UNIT 1651

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	2004/0161433	08/19/04	Teshigawara et al.	424	277.1	
	AB	2004/0175373	09/09/04	Berenson et al.	424	93.71	
	AC	2004/0180050	09/16/04	Hoffman	424	144.1	
	AD	2004/0180808	09/16/04	Nye et al.	514	2	
	AE	2004/0185048	09/23/04	Strom et al.	424	145.1	
	AF	2004/0241162	12/02/04	Berenson et al.	424	144.1	
	AG	2005/0003484	01/06/05	Hirano et al.	435	69.1	
	AH	2005/0084967	04/21/05	Berenson et al.	435	372	
	AI	2005/0153447	07/14/05	Berenson et al.	435	372	
	AJ	2005/0214942	09/29/05	Berenson et al.	435	372	
	AK	2005/0226857	10/13/05	Bonyhadi et al.	424	93.7	
	AL	2006/0039909	02/23/06	Hunig	424	144.1	
	AM	2006/0121005	06/08/06	Berenson et al.	424	93.7	
	AN	2006/0246587	11/02/06	June et al.	435	456	
	AO	2006/0286089	12/21/06	Berenson et al.	424	131.1	
	AP	2007/0212767	09/13/07	Bonyhadi et al.	435	173.8	
	AQ	2007/0274974	11/29/07	Bonyhadi et al.	424	93.71	
	AR	08/253,964		June et al.	435	240.2	06/03/94
	AS	60/375,733		Bonyhadi et al.			04/26/02
	AT						
	AU						
	AV						
	AW						
	AX						

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 980034.417C5	APPLICATION NO. 10/762,210
	APPLICANTS Ronald J. Berenson et al.	
	FILING DATE January 20, 2004	GROUP ART UNIT 1651

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AA	WO 86/04334	07/31/86	WIPO		
	AB	0 242 216	10/21/87	EP		
	AC	WO 89/05657	06/29/89	WIPO		
	AD	0 336 379	10/11/89	EP		
	AE	WO 90/05541	05/31/90	WIPO		
	AF	WO 90/10449	09/20/90	WIPO		
	AG	WO 91/06319	05/16/91	WIPO		
	AH	0 448 057	09/25/91	EP		
	AI	WO 91/15236	10/17/91	WIPO		
	AJ	WO 91/18629	12/12/91	WIPO		
	AK	WO 92/00092	01/09/92	WIPO		
	AL	WO 92/06117	04/16/92	WIPO		
	AM	WO 92/09628	06/11/92	WIPO		
	AN	WO 92/15671	09/17/92	WIPO		
	AO	WO 93/02690	02/18/93	WIPO		
	AP	WO 93/14789	08/05/93	WIPO		
	AQ	WO 93/19605	10/14/93	WIPO		
	AR	WO 93/19767	10/14/93	WIPO		
	AS	WO 93/20185	10/14/93	WIPO		
	AT	WO 93/20186	10/14/93	WIPO		
	AU	WO 93/24127	12/09/93	WIPO		
	AV	WO 93/24136	12/09/93	WIPO		

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 980034.417C5	APPLICATION NO. 10/762,210
	APPLICANTS Ronald J. Berenson et al.	
	FILING DATE January 20, 2004	GROUP ART UNIT 1651

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AA	WO 94/02156	02/03/94	WIPO		
	AB	WO 94/03202	02/17/94	WIPO		
	AC	WO 94/12196	06/09/94	WIPO		
	AD	WO 94/18317	08/18/94	WIPO		
	AE	WO 94/19009	09/01/94	WIPO		
	AF	WO 94/23734	10/27/94	WIPO		
	AG	WO 94/28912	12/22/94	WIPO		
	AH	WO 94/28926	12/22/94	WIPO		
	AI	WO 94/29436	12/22/94	WIPO		
	AJ	WO 95/00642	01/05/95	WIPO		
	AK	WO 95/03408	02/02/95	WIPO		
	AL	WO 95/09652	04/13/95	WIPO		
	AM	WO 95/13082	05/18/95	WIPO		
	AN	WO 95/16775	06/22/95	WIPO		
	AO	0 521 897	06/28/95	EP		
	AP	WO 95/20649	08/03/95	WIPO		
	AQ	WO 95/21251	08/10/95	WIPO		
	AR	WO 95/24910	09/21/95	WIPO		
	AS	WO 95/32735	12/07/95	WIPO		
	AT	WO 95/33770	12/14/95	WIPO		
	AU	WO 95/33823	12/14/95	WIPO		
	AV	WO 96/06929	03/07/96	WIPO		

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 980034.417C5	APPLICATION NO. 10/762,210
	APPLICANTS Ronald J. Berenson et al.	
	FILING DATE January 20, 2004	GROUP ART UNIT 1651

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AA	WO 96/14874	05/23/96	WIPO		
	AB	WO 96/15153	05/23/96	WIPO		
	AC	WO 96/30030	10/03/96	WIPO		
	AD	WO 96/33265	10/24/96	WIPO		
	AE	WO 96/34622	11/07/96	WIPO		
	AF	WO 96/37208	11/28/96	WIPO		
	AG	WO 96/38158	12/05/96	WIPO		
	AH	WO 97/00270	01/03/97	WIPO		
	AI	WO 97/02016	01/23/97	WIPO		
	AJ	WO 97/02045	01/23/97	WIPO		
	AK	WO 97/10361	03/20/97	WIPO		
	AL	WO 97/12633	04/10/97	WIPO		
	AM	0 340 109	05/28/97	EP		
	AN	WO 97/29182	08/14/97	WIPO		
	AO	WO 97/29183	08/14/97	WIPO		
	AP	WO 97/32970	09/12/97	WIPO		
	AQ	WO 97/34472	09/25/97	WIPO		
	AR	WO 97/34618	09/25/97	WIPO		
	AS	WO 97/37004	10/09/97	WIPO		
	AT	WO 97/39722	10/30/97	WIPO		
	AU	WO 97/44667	11/27/97	WIPO		
	AV	WO 97/46256	12/11/97	WIPO		
	AW	WO 98/13382	04/02/98	WIPO		

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 980034.417C5	APPLICATION NO. 10/762,210
	APPLICANTS Ronald J. Berenson et al.	
	FILING DATE January 20, 2004	GROUP ART UNIT 1651

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AA	WO 98/21314	05/22/98	WIPO		
	AB	WO 98/23728	06/04/98	WIPO		
	AC	WO 98/33891	08/06/98	WIPO		
	AD	WO 98/41090	09/24/98	WIPO		
	AE	WO 98/46083	10/22/98	WIPO		
	AF	WO 98/51820	11/19/98	WIPO		
	AG	WO 98/52615	11/26/98	WIPO		
	AH	WO 98/53048	11/26/98	WIPO		
	AI	197 22 888 A1	12/03/98	DE	X	
	AJ	WO 98/56819	12/17/98	WIPO		
	AK	WO 98/56823	12/17/98	WIPO		
	AL	WO 98/58541	12/30/98	WIPO		
	AM	WO 99/00137	01/07/99	WIPO		
	AN	WO 99/00143	01/07/99	WIPO		
	AO	WO 99/13904	03/25/99	WIPO		
	AP	2 304 268	04/01/99	CA		
	AQ	0 018 795	04/07/99	EP		
	AR	WO 99/21572	05/06/99	WIPO		
	AS	WO 99/21576	05/06/99	WIPO		
	AT	WO 99/24045	05/20/99	WIPO		
	AU	WO 99/25812	05/27/99	WIPO		
	AV	0 922 758 A2	06/16/99	EP		

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 980034.417C5	APPLICATION NO. 10/762,210
	APPLICANTS Ronald J. Berenson et al.	
	FILING DATE January 20, 2004	GROUP ART UNIT 1651

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AA	WO 99/29865	06/17/99	WIPO		
	AB	WO 99/29883	06/17/99	WIPO		
	AC	WO 99/34827	07/15/99	WIPO		
	AD	WO 99/36093	07/22/99	WIPO		
	AE	WO 99/38953	08/05/99	WIPO		
	AF	WO 99/42564	08/26/99	WIPO		
	AG	WO 99/51247	10/14/99	WIPO		
	AH	WO 99/52928	10/21/99	WIPO		
	AI	WO 99/55843	11/04/99	WIPO		
	AJ	WO 99/58977	11/18/99	WIPO		
	AK	WO 00/06588	02/10/00	WIPO		
	AL	WO 00/15767	03/23/00	WIPO		
	AM	WO 00/22124	04/20/00	WIPO		
	AN	WO 00/28000	05/18/00	WIPO		
	AO	WO 00/29008	05/25/00	WIPO		
	AP	WO 00/31138	06/02/00	WIPO		
	AQ	WO 00/44893	08/03/00	WIPO		
	AR	WO 00/47719	08/17/00	WIPO		
	AS	WO 00/51432	09/08/00	WIPO		
	AT	WO 00/52046	09/08/00	WIPO		
	AU	WO 00/53209	09/14/00	WIPO		
	AV	WO 00/56356	09/28/00	WIPO		
	AW	WO 00/57705	10/05/00	WIPO		

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 980034.417C5	APPLICATION NO. 10/762,210
	APPLICANTS Ronald J. Berenson et al.	
	FILING DATE January 20, 2004	GROUP ART UNIT 1651

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AA	WO 00/59538	10/12/00	WIPO		
	AB	WO 00/61157	10/19/00	WIPO		
	AC	WO 00/66764	11/09/00	WIPO		
	AD	WO 00/73432	12/07/00	WIPO		
	AE	WO 00/78348	12/28/00	WIPO		
	AF	WO 01/22970	04/05/01	WIPO		
	AG	WO 01/24771	04/12/01	WIPO		
	AH	WO 01/29192	04/26/01	WIPO		
	AI	WO 01/43694	06/21/01	WIPO		
	AJ	WO 01/43695	06/21/01	WIPO		
	AK	WO 01/49743	07/12/01	WIPO		
	AL	WO 01/52664	07/26/01	WIPO		
	AM	WO 01/70938	09/27/01	WIPO		
	AN	WO 01/85920	11/15/01	WIPO		
	AO	WO 01/87333	11/22/01	WIPO		
	AP	WO 01/88116	11/22/01	WIPO		
	AQ	WO 01/88159	11/22/01	WIPO		
	AR	WO 01/98357	12/27/01	WIPO		
	AS	WO 02/09674	02/07/02	WIPO		
	AT	WO 02/16414	02/28/02	WIPO		
	AU	WO 02/22790	03/21/02	WIPO		
	AV	WO 02/22805	03/21/02	WIPO		

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 980034.417C5	APPLICATION NO. 10/762,210
	APPLICANTS Ronald J. Berenson et al.	
	FILING DATE January 20, 2004	GROUP ART UNIT 1651

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AA	WO 02/28385	04/11/02	WIPO		
	AB	WO 02/060376	08/08/02	WIPO		
	AC	WO 02/087627	11/07/02	WIPO		
	AD	WO 02/092793	11/21/02	WIPO		
	AE	WO 03/006632	01/23/03	WIPO		
	AF	WO 03/020904	03/13/03	WIPO		
	AG	0 690 125 B1	04/23/03	EP		
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					
	AO					
	AP					
	AQ					
	AR					
	AS					
	AT					
	AU					
	AV					

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		ATTY. DOCKET NO. 980034.417C5	APPLICATION NO. 10/762,210
		APPLICANTS Ronald J. Berenson et al.	
		FILING DATE January 20, 2004	GROUP ART UNIT 1651
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Abbas et al., <i>Cellular and Molecular Immunology</i> , 3 rd Ed., W.B. Saunders Co., Philadelphia, PA, 1997, pp. 149, 155, 250, 266 and 413.	
	AB	Allegretta et al., "Homologies between T Cell Receptor Junctional Sequences Unique to Multiple Sclerosis and T Cells Mediating Experimental Allergic Encephalomyelitis," <i>J. of Clin. Invest.</i> , 94:105-109, July 1994.	
	AC	Altman et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes," <i>Science</i> , 274:94-96, October 4, 1996.	
	AD	Anderton et al., "Therapeutic potential of TCR antagonists is determined by their ability to modulate a diverse repertoire of autoreactive T cells," <i>Eur. J. Immunol.</i> , 29:1850-1857, 1999.	
	AE	"Attack on Cancer Soups Up Body's Immune Cells," <i>Cancer Weekly Plus</i> , December 21, 1998.	
	AF	Azuma et al., "B70 antigen is a second ligand for CTLA-4 and CD28," <i>Nature</i> , 366:76-79, November 4, 1993.	
	AG	Azuma et al., "Induction of apoptosis of activated murine splenic T cells by cycloprodigiosin hydrochloride, a novel immunosuppressant," <i>Immunopharmacol.</i> , 46:29-37, 2000.	
	AH	Bender et al., "T Cell Receptor Repertoire in Polymyositis: Clonal Expansion of Autoaggressive CD8 ⁺ T Cells," <i>J. Exp. Med.</i> , 181:1863-1868, May 1995.	
	AI	Bennett et al., "Help for cytotoxic-T-cell responses is mediated by CD40 signalling," <i>Nature</i> , 393:478-480, June 4, 1998.	
	AJ	Berenson et al., "Engraftment After Infusion of CD34 ⁺ Marrow Cells in Patients With Breast Cancer or Neuroblastoma," <i>Blood</i> , 77(8):1717-1722, April 15, 1991.	
	AK	Bernstein et al., "Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4 ⁺ T cells to HIV-infected persons," <i>Clin. Immunol.</i> , 111:262-274, 2004.	
	AL	Bishop et al., "High-Dose Therapy and Peripheral Blood Progenitor Cell Transplantation: Effects of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on the Autograft," <i>Blood</i> , 83(2):610-616, January 15, 1994.	
	AM	Bishop et al., "Assessing Apoptosis of Developing T Cells by Flow Cytometry" in <i>Methods in Molecular Biology</i> , vol. 134: <i>T Cell Protocols: Development And Activation</i> , Kearsse Ed., Humana Press, Tolowa, NJ, 1999, pp. 117-131.	
EXAMINER		DATE CONSIDERED	
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).			

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	980034.417C5	10/762,210
	APPLICANTS	
	Ronald J. Berenson et al.	
	FILING DATE	GROUP ART UNIT
	January 20, 2004	1651

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AA	Boehncke et al., "T-Cell-Receptor Repertoire in Chronic Plaque-Stage Psoriasis Is Restricted and Lacks Enrichment of Superantigen-Associated V β Regions," <i>J. Invest. Dermatol.</i> , 104:725-728, May 1995.
AB	Boerner et al., "Production of an Antigen-Specific Human Monoclonal Antibodies from in Vitro-Primed Human Splenocytes," <i>J. Immunol.</i> , 147(1):86-95, July 1991.
AC	Borthwick et al., "Loss of CD28 expression on CD8 ⁺ T cells is induced by IL-2 receptor γ chain signaling cytokines and type I IFN, and increases susceptibility to activation-induced apoptosis," <i>Int. Immunol.</i> , 12(7):1005-1013, 2000.
AD	Bour et al., "T-Cell Repertoire Analysis in Chronic Plaque Psoriasis Suggests an Antigen-Specific Immune Response," <i>Human Immunol.</i> , 60:665-676, 1999.
AE	Broder et al., "The Suppressor-Cell Network in Cancer," <i>New Eng. J. Med.</i> , 299(23):1281-1284, December 7, 1978.
AF	Broomé et al., "Preferential V β 3 usage by hepatic T lymphocytes in patients with primary sclerosing cholangitis," <i>J. Hepatol.</i> , 26:527-534, 1997.
AG	Brüggemann et al., "Production of human antibody repertoires in transgenic mice," <i>Curr. Opin. Biotechnol.</i> , 8:455-458, 1997.
AH	Bruserud et al., "Cyclosporine A and FK506 Show Similar Immunosuppressive Effects on Long-term <i>in Vitro</i> T-Cell Proliferation," <i>Int. J. Immunopharmac.</i> , 15(2):93-97, 1993.
AI	Bulfone-Paus et al., "An Interleukin-2-IgG-Fas Ligand Fusion Protein Suppresses Delayed-Type Hypersensitivity in Mice by Triggering Apoptosis in Activated T Cells as a Novel Strategy for Immunosuppression," <i>Transplantation</i> , 69(7):1386-1391, April 15, 2000.
AJ	Carpenter et al., "Non-FcR-Binding, Humanized Anti-CD3 Antibody Hu291 Induces Apoptosis of Human T Cells More Effectively Than OKT3 and Is Immunosuppressive In Vivo," <i>Transplant. Proc.</i> , 32(7):1545-1546, November 2000.
AK	Carpenter et al., "Non-Fc Receptor-Binding Humanized Anti-CD3 Antibodies Induce Apoptosis of Activated Human T Cells," <i>J. Immunol.</i> , 165:6205-6213, 2000.
AL	Carroll et al., "Accelerating the induction of Fas-mediated T cell apoptosis: a strategy for transplant tolerance?," <i>Clin. Exp. Immunol.</i> , 126:589-597, 2001.
AM	Cella et al., "Ligation of CD40 on Dendritic Cells Triggers Production of High Levels of Interleukin-12 and Enhances T Cell Stimulatory Capacity: T-T Help via APC Activation," <i>J. Exp. Med.</i> , 184:747-752, August 1996.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is inconformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 980034.417C5	APPLICATION NO. 10/762,210
	APPLICANTS Ronald J. Berenson et al.	
	FILING DATE January 20, 2004	GROUP ART UNIT 1651

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AA	Chen et al., "Ex vivo expansion of dendritic-cell-activated antigen-specific CD4(+) T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: Potential for adoptive T cell immunotherapy," <i>Clin. Immunol.</i> , 119:21-31, 2006.
AB	Christen et al., "Apoptosis of Autoreactive CD8 Lymphocytes as a Potential Mechanism for the Abrogation of Type 1 Diabetes by Islet-Specific TNF- α Expression at a Time When the Autoimmune Process Is Already Ongoing," <i>Ann. N.Y. Acad. Sci.</i> , 958:166-169, 2002.
AC	Cioca et al., "Apoptosis of Peripheral Blood Lymphocytes is Induced by Catecholamines," <i>Jpn. Heart J.</i> , 41:385-398, 2000.
AD	Claret et al., "Characterization of T Cell Repertoire in Patients with Graft-Versus-Leukemia After Donor Lymphocyte Infusion," <i>J. Clin. Invest.</i> , 100(4):855-866, August 1997.
AE	Combadière et al., "Selective Induction of Apoptosis in Mature T Lymphocytes by Variant T Cell Receptor Ligands," <i>J. Exp. Med.</i> , 187(3):349-355, February 2, 1998.
AF	Dalum et al., "Therapeutic antibodies elicited by immunization against TNF- α " <i>Nat. Biotechnol.</i> , 17:666-669, July 1999.
AG	Dao et al., "Natural Human Interferon- α Augments Apoptosis in Activated T Cell Line," <i>Cellular Immunol.</i> , 155:304-311, 1994.
AH	Davey et al., "TCRB Clonotypes Are Present in CD4+ T Cell Populations Prepared Directly from Rheumatoid Synovium," <i>Human Immunol.</i> , 55:11-21, 1997.
AI	Davies, "A New Role for Methimazole in Autoimmune Thyroid Disease: Inducing T Cell Apoptosis," <i>Thyroid</i> , 10(7):525-526, July 2000.
AJ	Di Renzo et al., "Enhanced apoptosis of T cells in common variable immunodeficiency (CVID): role of defective CD28 co-stimulation," <i>Clin. Exp. Immunol.</i> , 120:503-511, 2000.
AK	Di Sabatino et al., "Apoptosis and peripheral blood lymphocyte depletion in coeliac disease," <i>Immunol.</i> , 103:435-440, 2001.
AL	Ebata et al., "Rapid induction of CD95 ligand and CD4 ⁺ T cell-mediated apoptosis by CD137 (4-1BB) costimulation," <i>Eur. J. Immunol.</i> , 31:1410-1416, 2001.
AM	Ebert et al., "Lymphocyte apoptosis: induction by gene transfer techniques," <i>Gene Ther.</i> , 4:296-302, 1997.
AN	Epperson et al., "Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process," <i>Leukemia Res.</i> , 25:1075-1083, 2001.
AO	Freedman et al., "B7, A B Cell-Restricted Antigen that Identifies Preactivated B Cells," <i>J. Immunol.</i> , 139(10):3260-3267, November 15, 1987.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		ATTY. DOCKET NO. 980034.417C5	APPLICATION NO. 10/762,210
		APPLICANTS Ronald J. Berenson et al.	
		FILING DATE January 20, 2004	GROUP ART UNIT 1651
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Freeman et al., "B7, A New Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic B Cells," <i>J. Immunol.</i> , 143(8):2714-2722, October 15, 1989.	
	AB	Freeman et al., "Cloning of B7-2: A CTLA-4 Counter-receptor that Costimulates Human T Cell Proliferation," <i>Science</i> , 262:909-911, November 5, 1993.	
	AC	Freeman et al., "Structure, Expression, and T Cell Costimulatory Activity of the Murine Homologue of the Human B Lymphocyte Activation Antigen B7," <i>J. Exp. Med.</i> , 174:625-631, September 1991.	
	AD	Freeman et al., "Murine B7-2, an Alternative CTLA4 Counter-receptor that Costimulates T Cell Proliferation and Interleukin 2 Production," <i>J. Exp. Med.</i> , 178:2185-2192, December 1993.	
	AE	Freudenthal et al., "The distinct surface of human blood dendritic cells, as observed after an improved isolation method," <i>Proc. Natl. Acad. Sci. USA</i> , 87:7698-7702, October 1990.	
	AF	Gailit et al., "Wound repair in the context of extracellular matrix," <i>Curr. Opin. Cell Biol.</i> , 6:717-725, 1994.	
	AG	Gong et al., "Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells," <i>Proc. Natl. Acad. Sci. USA</i> , 95:6279-6283, May 1998.	
	AH	Gorochov et al., "Perturbation of CD4 ⁺ and CD8 ⁺ T-cell repertoires during progression to AIDS and regulation of the CD4 ⁺ repertoire during antiviral therapy," <i>Nat. Med.</i> , 4(2):215-221, February 1998.	
	AI	Hami et al., "Optimizing the Efficiency, Reproducibility and Cost of the Xcellerate™ Process for Clinical Delivery of Activated T Cells," <i>Blood</i> , 98(11 Part 2):336b-337b, Abstract 5112, 2001.	
	AJ	Hancock et al., "Keratinocyte Growth Regulation by the Products of Immune Cells," <i>J. Exp. Med.</i> , 168:1395-1402, October 1988.	
	AK	Hersh et al., "Impaired in Vitro Lymphocyte Transformation in Hodgkin's Disease," <i>New Eng. J. Med.</i> , 273(19):1006-1012, November 4, 1965.	
	AL	Hewitt, "Xcellerating cancer treatment," <i>BioVenture View</i> , 18(7):19, April 8, 2003.	
	AM	Imura et al., "The Human OX40/gp34 System Directly Mediates Adhesion of Activated T Cells to Vascular Endothelial Cells," <i>J. Exp. Med.</i> , 183:2185-2195, May 1996.	
	AN	Iruela-Arispe et al., "Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells <i>in vitro</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 88:5026-5030, June 1991.	
EXAMINER		DATE CONSIDERED	
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).			

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	980034.417C5	10/762,210
	APPLICANTS	
	Ronald J. Berenson et al.	
	FILING DATE	GROUP ART UNIT
	January 20, 2004	1651

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AA	Izumi et al., "Transforming Growth Factor β_1 Stimulates Type II Collagen Expression in Cultured Periosteum-Derived Cells," <i>J. Bone and Min. Res.</i> , 7(1):115-121, 1992.
AB	Jakobovits et al., "Production of Antigen-Specific Human Antibodies from Mice Engineered with Human Heavy and Light Chain YACs ^a ," <i>Ann. N.Y. Acad. Sci.</i> , 764:525-535, September 29, 1995.
AC	Janeway et al., <i>Immunobiology: The Immune System in Health and Disease</i> , Garland Publishing Inc., London, 1994, pp. 11:19-11:31.
AD	Jin et al., "Costimulation of T Cells with Immobilized Anti-CD3/Anti-CD28 (OKT3/9.3) Induces and Maintains Non-MHC Restricted Cytotoxicity," <i>Blood</i> , 88(10):41b, Abstract 2892, 1996.
AE	Jingushi et al., "Acidic Fibroblast Growth Factor (aFGF) Injection Stimulates Cartilage Enlargement and Inhibits Cartilage Gene Expression in Rat Fracture Healing," <i>J. Orthopaedic Res.</i> , 8:364-371, 1990.
AF	Joyce et al., "Transforming Growth Factor- β and the Initiation of Chondrogenesis and Osteogenesis in the Rat Femur," <i>J. Cell. Biol.</i> , 110:2195-2207, June 1990.
AG	Kern et al., "Cancer Cachexia," <i>J. Parenteral and Enteral Nutrition</i> , 12(3):286-298, 1998.
AH	Kitajima et al., "T Cell-Mediated Terminal Maturation of Dendritic Cells: Loss of Adhesive and Phagocytotic Capacities," <i>J. Immunol.</i> , 157:2340-2347, 1996.
AI	Knight et al., "Dendritic Cells and HIV Infection," in <i>Accessory Cells in HIV and Other Retroviral Infections</i> , Racz et al. Eds., Basel Karger, 1991, pp. 145-154.
AJ	Kugler et al., "Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids," <i>Nat. Med.</i> , 6(3):332-336, March 2000.
AK	Lâhdevirta et al., "Elevated Levels of Circulating Cachectin/Tumor Necrosis Factor in Patients with Acquired Immunodeficiency Syndrome," <i>Am. J. Med.</i> , 85:289-291, 1988.
AL	Leporrier, "Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia," <i>Hematol. J.</i> , 5(Supp. 1):S10-9, 2004. [Abstract Only]
AM	Li et al., "CDR3 Sequence Motifs Shared by Oligoclonal Rheumatoid Arthritis Synovial T Cells. Evidence for an Antigen-driven Response," <i>J. Clin. Invest.</i> , 94:2525-2531, December 1994.
AN	Lim et al., "Spread of Clonal T-Cell Expansions in Rheumatoid Arthritis Patients," <i>Human Immunol.</i> , 48:77-83, 1996.
AO	Liuzzo et al., "Monoclonal T-Cell Proliferation and Plaque Instability in Acute Coronary Syndromes," <i>Circulation</i> , 102:2883-2888, June 27, 2000.
AP	Mantegazza et al., "Analysis of T Cell Receptor Repertoire of Muscle-infiltrating T Lymphocytes in Polymyositis. Restricted Va/ β Rearrangements May Indicate Antigen-driven Selection," <i>J. Clin. Invest.</i> , 91:2880-2886, June 1993.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		ATTY. DOCKET NO. 980034.417C5	APPLICATION NO. 10/762,210
		APPLICANTS Ronald J. Berenson et al.	
		FILING DATE January 20, 2004	GROUP ART UNIT 1651
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Martin et al., "Diversity in Fine Specificity and T Cell Receptor Usage of the Human CD4 ⁺ Cytotoxic T Cell Response Specific for the Immunodominant Myelin Basic Protein Peptide 87-106," <i>J. Immunol.</i> , 148(5):1359-1366, March 1, 1992.	
	AB	Martin et al., "T-Cell Receptors and Autoimmune Thyroid Disease – Signposts for T-Cell-Antigen Driven Diseases," <i>Intern. Rev. Immunol.</i> , 18:111-140, 1999.	
	AC	Meuer et al., "An Alternative Pathway of T-Cell Activation: A Functional Role for the 50 kd T11 Sheep Erythrocyte Receptor Protein," <i>Cell</i> , 36:897-906, April 1984.	
	AD	Monji et al., "Activated T Cells and Their Culture Supernatants Mediate Differentiation and Maturation of Monocyte-Derived Dendritic Cells," <i>Blood</i> , 98(11 part 1):231a, Abstract 965, November 16, 2001.	
	AE	"New Approach Shows Promise to Use Patient's Own T Cells to Treat Cancer," <i>PR Newswire</i> , pp. 1774, December 7, 1998.	
	AF	Ogata, "Parathyroid Hormone-Related Protein as a Potential Target of Therapy for Cancer-Associated Morbidity," <i>Cancer Supplement</i> , 88(12):2909-2911, June 15, 2000.	
	AG	Racioppi et al., "Defective dendritic cell maturation in a child with nucleotide excision repair deficiency and CD4 lymphopenia," <i>Clin. Exp. Immunol.</i> , 126:511-518, 2001.	
	AH	Ramsauer et al., "Imunohistochemical Study of Langerhans' Cells in the Skin of HIV-1-Infected Patients with and without Kaposi's Sarcoma," <i>Accessory Cells in HIV and Other Retroviral Infections</i> , in Racz et al. Eds., Basel Karger, 1991, pp. 155-161.	
	AI	Reddy et al., "A Monocyte Conditioned Medium Is More Effective Than Defined Cytokines in Mediating the Terminal Maturation of Human Dendritic Cells," <i>Blood</i> , 90(9):3640-3646, November 1, 1997.	
	AJ	Ridge et al., "A conditioned dendritic cell can be a temporal bridge between a CD4 ⁺ T-helper and a T-killer cell," <i>Nature</i> , 393:474-478, June 4, 1998.	
	AK	Rissoan et al., "Reciprocal Control of T Helper Cell and Dendritic Cell Differentiation," <i>Science</i> , 283:1183-1186, February 19, 1999.	
	AL	Rosenberg et al., "Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients With Metastatic Melanoma: A Preliminary Report," <i>New Eng. J. of Med.</i> , 319(25):1676-1680, December 22, 1988.	
	AM	Sage et al., "Collagen Synthesis by Bovine Aortic Endothelial Cells in Culture," <i>Biochem.</i> , 18(24):5433-5442, November 24, 1979.	
	AN	Scanlan et al., "Molecular cloning of fibroblast activation protein α , a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers," <i>Proc. Natl. Acad. Sci. USA</i> , 91:5657-5661, June 1994.	
EXAMINER		DATE CONSIDERED	
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).			

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		ATTY. DOCKET NO. 980034.417C5	APPLICATION NO. 10/762,210
		APPLICANTS Ronald J. Berenson et al.	
		FILING DATE January 20, 2004	GROUP ART UNIT 1651
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Schoenberger et al., "T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions," <i>Nature</i> , 393:480-483, June 4, 1998.	
	AB	Schuurhuis et al., "Immature Dendritic Cells Acquire CD8 ⁺ Cytotoxic T Lymphocyte Priming Capacity Upon Activation by T Helper Cell-Independent or -Dependent Stimuli," <i>J. Exp. Med.</i> , 192(1):145-150, July 3, 2000.	
	AC	Smith, "Technology evaluation: C242-DM1, ImmunoGen Inc.," <i>Curr. Opin. Mol. Therapeutics</i> , 3(2):198-203, 2001.	
	AD	Staiano-Coico et al., "Human Keratinocyte Culture. Identification and Staging of Epidermal Cell Subpopulations," <i>J. Clin. Invest.</i> , 77(2):396-404, February 1986.	
	AE	Takashima et al., "T Cell-Mediated Terminal Maturation of Dendritic Cells, a Critical Transition into Fully Potent Antigen Presenting Cells," <i>Pathologie Biologie (Paris)</i> , 46(1):53-60, January 1998.	
	AF	Thomson et al., "Embryonic Stem Cell Lines Derived From Human Blastocysts," <i>Science</i> , 282:1145-1147, November 6, 1998.	
	AG	Tolsma et al., "Peptides Derived From Two Separate Domains of the Matrix Protein Thrombospondin-1 Have Anti-Angiogenic Activity," <i>J. Cell. Biol.</i> , 122(2):497-511, July 1993.	
	AH	Vogel et al., "Modulation of Endothelial Cell Proliferation, Adhesion, and Motility by Recombinant Heparin-Binding Domain and Synthetic Peptides From the Type I Repeats of Thrombospondin," <i>J. Cell. Biochem.</i> , 53:74-84, 1993.	
	AI	Weishaupt et al., "Antigen therapy eliminates T cell inflammation by apoptosis: Effective treatment of experimental autoimmune neuritis with recombinant myelin protein P2," <i>Proc. Natl. Acad. Sci. USA</i> , 94:1338-1343, February 1997.	
	AJ	Weishaupt et al., "Glucocorticosteroids modulate antigen-induced T cell apoptosis in experimental autoimmune neuritis and cause T cell proliferation in situ," <i>Acta Neuropathologica</i> , 102(1):75-82, July 2001.	
	AK	White et al., "The roles of Fas, Fas ligand and Bcl-2 in T cell apoptosis in the central nervous system in experimental autoimmune encephalomyelitis," <i>J. Neuroimmunol.</i> , 82:47-55, 1998.	
	AL	Wong et al., "Analysis of the Peripheral T-Cell Receptor V β Repertoire in Newly Diagnosed Patients with Type I Diabetes," <i>Autoimmunity</i> , 18:77-83, 1994.	
	AM	Wu et al., "TCR Gene Usage in Experimental Autoimmune Myasthenia Gravis Pathogenesis," <i>J. Immunol.</i> , 154:3603-3610, 1995.	
EXAMINER		DATE CONSIDERED	
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).			

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	980034.417C5	10/762,210
	APPLICANTS	
	Ronald J. Berenson et al.	
	FILING DATE	GROUP ART UNIT
	January 20, 2004	1651

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AA	Wu et al., "Conserved T-cell receptor β -chain CDR3 sequences in IgA nephropathy biopsies," <i>Kidney Int.</i> , 55:109-119, 1999.
AB	Wucherpfennig et al., "T Cell Receptor V_{α} - V_{β} Repertoire and Cytokine Gene Expression in Active Multiple Sclerosis Lesions," <i>J. Exp. Med.</i> , 175:993-1002, April 1992.
AC	Xiao et al., "Mechanisms of recovery from experimental allergic encephalomyelitis induced with myelin basic protein peptide 68-86 in Lewis rats: a role for dendritic cells in inducing apoptosis of CD4 ⁺ T cells," <i>J. Neuroimmunol.</i> , 97:25-36, 1999.
AD	Yang et al., "A Common Pathway for T Lymphocyte Activation Involving Both the CD3-Ti Complex and CD2 Sheep Erythrocyte Receptor Determinants," <i>J. Immunol.</i> , 137(4):1097-1100, August 15, 1986.
AE	Yang et al., "Apoptosis of infiltrating cells in experimental autoimmune uveoretinitis," <i>Chinese Med. J.</i> , 113(7):643-646, 2000.
AF	Young et al., "Dendritic cells: expansion and differentiation with hematopoietic growth factors," <i>Curr. Opin. Hematol.</i> , 6:135-144, 1999.
AG	Yu et al., "Apoptosis of CD4 ⁺ T cells occurs in experimental autoimmune anterior uveitis (EAAU)," <i>Clin. Exp. Immunol.</i> , 118:357-363, 1999.
AH	Zipp et al., "Dual effect of glucocorticoids on apoptosis of human autoreactive and foreign antigen-specific T cells," <i>J. Neuroimmunol.</i> , 110(1-2):214-222, October 2000.
AI	
AJ	
AK	
AL	
AM	
AN	
AO	
AP	

EXAMINER /Taeyoon Kim/

DATE CONSIDERED 12/28/2008

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).